

PEPTIDE

# Tesamorelin

Stabilized GHRH(1-44) analog; FDA-approved to reduce excess abdominal visceral fat in HIV patients via pulsatile GH release.

BIOGATE · GREEN    POSTERIOR 89.6%    MW 5135.9    44AA

SEQUENCE

YDAIIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARRL

Modifications: trans-3-hexenoyl N-terminal

## PDA-V1 chain of custody

Outer hash

200-  
f49731f0f47e0220f4c99210f4b06240f4fbf230f4e2c260f52e525

Merkle root

15520-  
b4816520cdb17520e6e18521001195211941a5213271b5214ba1c52164d

Inputs

a2bc86f3a1bc8560a4bc8a19a3bc8886a6bc8d3fa5bc8baca8bc906

TEE attestation

b407b0f6b507b289b207add0b307af63b807b742b907b8d5b607b41cb707b5af

## Living Outcome Oracle

± 60.2

<sup>2</sup> =7.0

**P(success) = 89.6%**

95% CI [77.6%, 100.0%]

## Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

## Citations

GRADE A

2007 · N Engl J Med

**Metabolic effects of a growth hormone-releasing factor in patients with HIV**

Falutz J et al.

PMID 18046029